ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

Conclusions The RP2D for AZD5363 is 320  mg BID, 4 days on/3 days off, in combination with full dose DP for mCRPC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research